# From Pakistan to Shanghai: A CAR-T Journey Fighting Relapsed Lymphoma

- Link: https://www.thailand-business-news.com/pr-news/from-pakistan-to-shanghai-a-car-t-journey-fighting-relapsed-lymphoma
- Published: 2026-05-25T07:41:00+07:00
- Author: PR Newswire

SHANGHAI, May 25, 2026 /PRNewswire/ — A 36-year-old Pakistani patient has achieved
encouraging early recovery after receiving personalized CAR-T immunotherapy at Jiahui
International Cancer Center in Shanghai, following exhausting standard treatments
for aggressive recurrent blood cancer.

Muhammad, a hospital staff member from Quetta, Pakistan, suffered from diffuse large
B-cell lymphoma (DLBCL). After multiple chemotherapy courses and a failed bone marrow
transplant, his disease progressed to Stage IVB by early 2026, with widespread metastasis
in the lungs, pleura and bones, accompanied by severe, intractable pain. Local doctors
confirmed no further effective conventional treatments and recommended overseas 
advanced therapy, with his overseas treatment application officially approved by
Pakistan’s national medical board.

After evaluating medical institutions across multiple countries, Muhammad chose 
Jiahui for its efficient consultation services and thoughtful patient guidance throughout
the pre-treatment process.

Given Muhammad’s complex condition along with extensive tumor burden, Dr. Hao Siguo,
the Chief Hematology Consultant, developed a personalized CAR-T therapy regimen 
for him following remote consultation. To reduce tumor volume ahead of cell infusion,
he designed a bridging therapy combining chemotherapy and local radiotherapy. The
strategy later successfully lowered infusion-associated risks and improved overall
treatment efficacy.

With stable vital organ function, the multidisciplinary team proceeded with the 
customized therapy. After the patient underwent lymphocyte collection, the first
step of the CAR-T process, and preparatory therapies to optimize his physical condition
for safe cell infusion, Muhammad received his personalized CAR-T cell infusion on
April 23, 2026. During inpatient observation, he only experienced mild, manageable
cytokine release syndrome with no severe neurotoxicity. Significant clinical improvements
emerged rapidly: his severe cancer pain was greatly relieved, and reliance on opioid
medications was drastically reduced. Pre-discharge tests showed shrinking lesions
and normalized key laboratory indicators.

Throughout his treatment, Jiahui’s international care team provided full support
including professional translation services and halal catering to accommodate his
cultural and religious needs.

He spoke positively about his experience in China and the support he received, saying,"
Chinese people are very cooperative. The doctors, nurses, and staff were very supportive."
Discharged on May 7, 2026, Muhammad will complete regular follow-up imaging and 
monitoring back in Pakistan.

The case highlights Jiahui International Cancer Center’s expertise in refractory
lymphoma CAR-T therapy and its capacity to deliver standardized, patient-centered
cross-border medical services for global patients with complex oncological conditions.

Read more: [https://jiahui.com/en/news/211](https://jiahui.com/en/news/211)

**Contact the International Office**
Email: [internationaloffice@jiahui.com](https://www.thailand-business-news.com/pr-news/internationaloffice@jiahui.com)
WhatsApp: +852 4619 1904

---

  |  This article was produced by Cision PR Newswire, our trusted news partner. The views expressed and the content presented here are solely those of the author and may not fully reflect the opinions of Thailand Business News. |

---

 
**Read the original article :** [From Pakistan to Shanghai: A CAR-T Journey Fighting Relapsed Lymphoma ](http://www.prnasia.com/story/archive/4966254_AE66254_0?rand=184833)
